References
- Paruchuri P, Godkar D, Anandacoomarswamy D, et al. Rare case of serotonin syndrome with therapeutic doses of paroxetine. Am J Ther. 2006;13:550–552.
- Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–1120.
- Daniels RJ. Serotonin syndrome due to venlafaxine overdose. J Accid Emerg Med. 1998;15:333–334.
- Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004;26:1355–1367.
- Forrester MB. Adult metaxalone ingestions reported to Texas poison control centers, 2000–2006. Hum Exp Toxicol. 2010;29:55–62.
- Poklis JL, Ropero-Miller JD, Garside D, et al. Metaxalone (Skelaxin)-related death. J Anal Toxicol. 2004;28:537–541.
- Moore KA, Levine B, Fowler D. A fatality involving metaxalone. Forensic Sci Int. 2005;149:249–251.
- Bishop-Freeman SC, Miller A, Hensel EM, et al. Postmortem metaxalone (Skelaxin®) data from North Carolina. J Anal Toxicol. 2015;39:629–636.
- Bosak AR, Skolnik AB. Serotonin syndrome associated with metaxalone overdose. J Med Toxicol. 2014;10:402–405.
- Martini DI, Nacca N, Haswell D, et al. Serotonin syndrome following metaxalone overdose and therapeutic use of a selective serotonin reuptake inhibitor. Clin Toxicol. 2015;53:185–187.
- Surmaitis RM, Nappe TM, Cook MD. Serotonin syndrome associated with therapeutic metaxalone in a patient with cirrhosis. Am J Emerg Med. 2016;34:346.e5–346.e6.
- Igneri L, Shaw C, Solomon B. Life-threatening serotonin syndrome after administration of metaxalone in a patient on citalopram. Crit Care Med. 2013;41:A285.
- Baselt RC. Disposition of toxic drugs and chemicals in man. 10th ed. Seal Beach, CA: Biomedical Publications; 2014.
- Green AR, Mitchell BD, Tordoff AFC, et al. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol. 1977;60:343–349.
- MAO-GloTM Assay, Technical Bulletin [cited 2014 Nov 14]. Available from: https://www.promega.com/-/media/files/resources/protocols/technical-bulletins/101/mao-glo-assay-protocol.pdf
- Gaweska H, Fitzpatrick PF. Structures and mechanism of the monoamine oxidase family. Biomol Concepts. 2011;2:365–377.
- Isbister GK, Hackett LP, Dawson AH, et al. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol. 2003;56:441–450.
- Grison-Hernando H, Monteil-Ganiere C, Guitton C, et al. Serotonin syndrome due to an overdose of moclobemide and venlafaxine: case report and review of the literature. Clin Exp Pharmacol. 2015;5:193.
- Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry. 2006;59:1046–1051.
- Pandit N, Singla RK, Shrivastava B. Current updates on oxazolidinone and its significance [Internet]. Int J Med Chem. 2012;2012:1. [cited 2018 Jan 30]. Available from: https://www.hindawi.com/journals/ijmc/2012/159285/.
- Azoyan P, Garnier R, Baud FJ, et al. [Acute toloxatone poisoning. Apropos of 122 cases]. Therapie. 1990;45:139–144.
- Frykberg RG, Gordon S, Tierney E, et al. Linezolid-associated serotonin syndrome. A report of two cases. J Am Podiatr Med Assoc. 2015;105:244–248.
- Gupta V, Karnik ND, Deshpande R, et al. Linezolid-induced serotonin syndrome. BMJ Case Rep. 2013;2013:bcr2012008199.
- Karkow DC, Kauer JF, Ernst EJ. Incidence of serotonin syndrome with combined use of linezolid and serotonin reuptake inhibitors compared with linezolid monotherapy. J Clin Psychopharmacol. 2017;37:518–523.
- Sacher J, Houle S, Parkes J, et al. Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John’s wort: an [11C]-harmine PET study. J Psychiatry Neurosci. 2011;36:375–382.
- Eddleston M, et al. Insecticides: organic phosphorus compounds and carbamates. In: Hoffman RS, Howland MA, Lewin NA, editors. Goldfrank’s toxicologic emergencies [Internet]. 10th ed. New York, NY: McGraw-Hill Education; 2015. [cited 2019 Apr 3]. Available from: accessemergencymedicine.mhmedical.com/content.aspx?aid = 1108435876.
- Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826–835.